Canopy Growth Corp (TSE:WEED – Get Free Report) Director David Angelo Lazzarato sold 22,380 shares of the firm’s stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of C$1.29, for a total transaction of C$28,870.20. Following the sale, the director owned 108,237 shares in the company, valued at approximately C$139,625.73. The trade was a 17.13% decrease in their position.
Canopy Growth Price Performance
TSE:WEED traded down C$0.05 during trading hours on Wednesday, hitting C$1.27. 1,422,628 shares of the stock traded hands, compared to its average volume of 1,569,084. The company has a quick ratio of 2.32, a current ratio of 3.04 and a debt-to-equity ratio of 40.27. Canopy Growth Corp has a 1 year low of C$1.18 and a 1 year high of C$3.28. The company has a market cap of C$537.26 million, a price-to-earnings ratio of -1.90, a price-to-earnings-growth ratio of -0.01 and a beta of 1.63. The stock has a 50 day moving average price of C$1.34 and a 200 day moving average price of C$1.40.
Canopy Growth (TSE:WEED – Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported C($0.03) earnings per share for the quarter. The firm had revenue of C$81.17 million during the quarter. Canopy Growth had a negative return on equity of 29.85% and a negative net margin of 73.95%. Sell-side analysts forecast that Canopy Growth Corp will post -0.69 EPS for the current fiscal year.
Analysts Set New Price Targets
Read Our Latest Report on Canopy Growth
About Canopy Growth
Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands.
Further Reading
- Five stocks we like better than Canopy Growth
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
- O’Reilly Automotive’s Stock Slump Hides a Stronger Business
- McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
- Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test
Receive News & Ratings for Canopy Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Canopy Growth and related companies with MarketBeat.com's FREE daily email newsletter.
